Global coagulation assays in patients with diabetes mellitus
| Autor: | Prahlad Ho, Hui Yin Lim, Mark Tacey, Anna Kwok, Harshal Hanumant Nandurkar, Brandon Lui, Suresh Varadarajan, Geoffrey A. Donnan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Type 2 diabetes Gastroenterology Fibrin Internal medicine Diabetes mellitus Fibrinolysis medicine Diseases of the blood and blood-forming organs fibrin Dialysis Type 1 diabetes Hematology biology medicine.diagnostic_test business.industry thromboelastography Original Articles medicine.disease thrombin Thromboelastography diabetes mellitus biology.protein Original Article fibrinolysis RC633-647.5 business |
| Zdroj: | Research and Practice in Thrombosis and Haemostasis Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021) |
| ISSN: | 2475-0379 |
| DOI: | 10.1002/rth2.12611 |
| Popis: | Background There is significant heterogeneity in the incidence and severity of diabetes‐associated vascular complications and there is no routine biomarker that accurately predicts these outcomes. This pilot study investigates the role of global coagulation assays in patients with diabetes mellitus. Methods In this cross‐sectional study, patients with diabetes not on anticoagulation or dialysis and without active malignancy were recruited from endocrinology clinics. Blood samples were collected for global coagulation assays including thromboelastography (TEG), thrombin generation using calibrated automated thrombogram (CAT), and fibrin generation and fibrinolysis using the overall hemostatic potential (OHP) assay. The results were compared with healthy controls. Results A total of 147 adult patients including 19 with type 1 diabetes (T1DM), 120 with type 2 diabetes (T2DM), and eight with latent autoimmune diabetes were recruited. Compared with 153 healthy controls, patients with diabetes demonstrated higher maximum amplitude (68.6 vs 60.2 mm, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text